Consumer demand for milk, butter and other dairy products was up in 2020, as more people ate at home. It’s a buying habit the dairy industry would like to see continue, after experiencing declining fluid milk sales in much of the previous decade.
A key to maintaining that demand is to continue sending positive messages to consumers about U.S. milk production, starting at the producer level, said Linda Tikofsky, DVM, Boehringer Ingelheim. “Producers understand consumer concerns about milk quality and should continue to do a good job of communicating to the public all the care and safeguards that go into milk production on today’s dairy farms. That includes more judicious use of antibiotics for management of mastitis infections.”
“Being more thoughtful about antibiotic use is necessary in preserving it as an important tool in our medical kits for the long term,” she said. “That involves understanding the disease process, principles of antibiotic use and the length of treatment, as well as making sure we’re matching the drug to the bug.”
In the case of severe clinical mastitis, cows need to be treated immediately, she added. “But with mild or moderate clinical mastitis, where there is abnormal milk or maybe swelling of the quarter, we can step back and consider the cow’s future in the herd, do a culture so we understand what’s causing the mastitis and then make a decision about which treatment is necessary — or maybe that no treatment is needed since some bacterial infections will cure on their own.”
With mild and moderate mastitis cases, waiting 24 hours for a culture result to make a more informed decision about treatment makes no difference to the health of the cow, the outcome of the disease or the cure rate, noted Tikofsky. “Not all bacterial causes can be treated with antibiotics, and a certain percent of cases will self-cure with supportive care.”
She recommends that producers work with their veterinarians to develop first- and second-line protocols for treatment of common diseases, including mastitis, to avoid unnecessary antibiotic use.
Pathogen-based treatment savings
Mastitis is often the No. 1 disease that many herds face, in terms of incidence. Its impact on the bottom line is another motivating factor in trying to reduce antibiotic use, said Michael Capel, DVM, a partner at Perry Vet, PLLC, Perry, New York, who works with dairies throughout the western part of the state.
“With pathogen-based mastitis therapy, we identify the type of bacteria causing the mastitis and only use antibiotics to treat those we know will respond to them, namely streptococci,” he said. “If coliform bacteria are cultured or no pathogen is cultured at all, we usually wouldn’t treat with an antibiotic. Depending on the profile of the bacteria causing mastitis, herds using pathogen-based mastitis therapy can reduce antibiotic use by up to 65%, versus blanket herd antibiotic treatment.”
Studies at Cornell University have shown that pathogen-based treatment results in $30 more profit per cow, on an annual basis.1 “For a 1,000-cow herd that adds up to $30,000 in financial upside per year in reduced labor, less antibiotic cost and more milk sold,” he said, “and with the same clinical outcomes as with blanket-based antibiotic treatment.”
Keys to prevention
After years of working with dairy operations of all sizes, Capel has observed three management areas that are key to mastitis prevention, and worth regularly reviewing with employees:
- Bedding management. Remove manure as soon as possible and keep plenty of fresh bedding under cattle so animals, and particularly udders, remain clean and dry.
- Teat-end cleanliness. Regularly reviewing the pre-milking teat-cleaning process with employees helps ensure that no steps are skipped or shortened. Taking a few extra seconds during cleaning to examine teat ends can also help identify any condition issues.
- Animal handling and environment. Keeping cows calm before milking is critical, and it starts when workers enter the barn. Cattle shouldn’t be startled or rushed to the parlor. Gentle handling also avoids muck splatters and injuries.
Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.
Respect for animals, humans and the environment guides us every day. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.
Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of $4.7 billion (4.1 billion euros) in 2020 and presence in more than 150 countries.
Boehringer Ingelheim Animal Health has a significant presence in the United States, with more than 3,100 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.
Boehringer Ingelheim
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim has been independent and family owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, with around 52,000 employees, we create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
In 2020, Boehringer Ingelheim achieved net sales of around $22.33 billion (19.57 billion euros). Our significant investment of over $4.2 billion (3.7 billion euros) in 2020 (18.9% of net sales) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
